Renew Biotechnologies, a US-based biotech company, announced on Thursday that it has named Steven Abbott as its new chief operating officer (COO).
In the new role, Abbott is to lead Wasatch BioLabs, a core Renew Biotechnologies subsidiary, from its present research and development phase into full-scale commercial operations.
Abbott has more than 15 years of experience in the biotechnology and life sciences industries. He has most recently served as vice president of Lab Operations at Flagship Biosciences, Inc. He has served in leadership positions at Q² Solutions, including director of Genomics Business Development and director of Global Genomics Lab Operations.
Chad Pollard, Renew Biotechnologies co-founder and CEO, said, 'We are excited to have Steven Abbott join our executive team at this pivotal point in our development. We are building a 20,000 sqft high-throughput clinical laboratory at Wasatch Biolabs to transition to full-scale clinical services. Steven's molecular diagnostics expertise and operational experience will be crucial in this shift. We are confident his leadership will drive the successful development and launch of our innovative sequencing-based diagnostic tools.'
Sanofi commits USD18m to boost diversity in clinical studies
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
Saniona reaches milestone in Boehringer Ingelheim partnership
Lipella granted patent for innovative drug delivery technology
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
PharmAbcine's PMC-403 Phase one clinical trial single ascending dose cohort receives safety approval
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
Lundbeck agrees to acquire Longboard Pharmaceuticals to enhance neuroscience pipeline